Bristol-Myers Squibb Company(BMY)Earnings, Financials & Key Ratios

BMY•NYSE

$56.92

$116.22B mkt cap·16.5× P/E·Price updated May 6, 2026

SectorHealthcare IndustryLarge Pharma Sub-IndustryLarge diversified branded pharma

AboutBristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.Show more

Revenue$48.19B-0.2%
EBITDA$16.56B-14.0%
Net Income$7.05B+178.8%
EPS (Diluted)3.45+178.2%
Gross Margin67.65%+19.1%
EBITDA Margin34.35%-13.8%
Operating Margin26.34%+31.7%
Net Margin14.63%+179.0%
ROE40.43%+203.6%
ROIC16.9%+36.2%
Debt/Equity2.55-18.5%
Interest Coverage7.08+314.2%

Analysis→Technical→

BMY Key Insights

Bristol-Myers Squibb Company (BMY) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Strong Piotroski F-Score: 8/9
✓FCF machine: 26.7% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Healthy dividend yield of 4.3%

✗Weaknesses

✗High debt to equity ratio of 2.5x

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

BMY Price & Volume

Bristol-Myers Squibb Company (BMY) stock price & volume — 10-year historical chart

Loading chart...

BMY Growth Metrics

Bristol-Myers Squibb Company (BMY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years11.27%

5 Years2.54%

3 Years1.45%

TTM1.78%

Profit CAGR

10 Years16.25%

5 Years-

3 Years3.69%

TTM34.25%

EPS CAGR

10 Years13.53%

5 Years-

3 Years5.36%

TTM33.57%

Return on Capital

10 Years14.84%

5 Years13.09%

3 Years14.61%

Last Year18.75%

BMY Recent Earnings

Bristol-Myers Squibb Company (BMY) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 11/12 qtrs (92%)●Beat Revenue 10/12 qtrs (83%)

Q2 2026Latest

Apr 30, 2026

EPS

$1.58

Est $1.42

+11.3%

Revenue

$11.5B

Est $10.9B

+5.1%

Q1 2026

Feb 5, 2026

EPS

$1.26

Est $1.23

+2.4%

Revenue

$12.5B

Est $12.3B

+1.8%

Q4 2025

Oct 30, 2025

EPS

$1.63

Est $1.52

+7.2%

Revenue

$12.2B

Est $11.9B

+3.1%

Q3 2025

Jul 31, 2025

EPS

$1.46

Est $1.09

+33.9%

Revenue

$12.3B

Est $11.4B

+7.2%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	Apr 30, 2026	$1.58vs $1.42+11.3%	$11.5Bvs $10.9B+5.1%
Q1 2026	Feb 5, 2026	$1.26vs $1.23+2.4%	$12.5Bvs $12.3B+1.8%
Q4 2025	Oct 30, 2025	$1.63vs $1.52+7.2%	$12.2Bvs $11.9B+3.1%
Q3 2025	Jul 31, 2025	$1.46vs $1.09+33.9%	$12.3Bvs $11.4B+7.2%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	FCF Yield	Debt / Equity
PFEPfizer Inc.Direct Competitor	150.4B	26.44	19.44	-1.65%	11.83%	8.34%	6.03%	0.78
MRKMerck & Co., Inc.Direct Competitor	279.49B	113.16	15.54	1.18%	28.12%	36.14%	4.42%	0.96
ABBVAbbVie Inc.Direct Competitor	364.63B	206.15	86.98	8.57%	6.91%	62.15%	4.89%
LLYEli Lilly and CompanyDirect Competitor	933.66B	988.19	43.06	44.7%	34.98%	101.17%	0.96%	1.60
JNJJohnson & JohnsonDirect Competitor	543.64B	225.59	38.96	4.3%	27.26%	31.69%	3.65%	0.51
AZNAstraZeneca PLCDirect Competitor	280.97B	181.24	27.71	8.63%	17.19%	22.24%	4.19%	0.61
GSKGSK plcDirect Competitor	101.32B	50.38	6.67	4.11%	19.19%	31.48%	7.81%	1.11
GILDGilead Sciences, Inc.Product Competitor	166.32B	133.48	351.26	6.04%	28.9%	37.62%	6.2%	1.39

Compare BMY vs Peers

Bristol-Myers Squibb Company (BMY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs PFE

Most directly comparable listed peer for BMY.

Scale Benchmark

vs LLY

Larger-name benchmark to compare BMY against a more recognizable public peer.

Peer Set

Compare Top 5

vs PFE, MRK, ABBV, LLY

BMY Income Statement

Bristol-Myers Squibb Company (BMY) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Sales/Revenue	20.78B	22.56B	26.14B	42.52B	46.38B	46.16B	45.01B	48.3B	48.19B	48.48B
Revenue Growth %	6.94%	8.59%	15.89%	62.62%	9.1%	-0.49%	-2.5%	7.32%	-0.22%	1.78%
Cost of Goods Sold	5.82B	6.49B	8.89B	20.82B	19.62B	19.67B	19.65B	20.87B	15.59B	15.15B
COGS % of Revenue	28%	28.75%	34.02%	48.96%	42.31%	42.61%	43.66%	43.2%	32.35%	-
Gross Profit	14.96B▲ 0%	16.07B▲ 7.5%	17.25B▲ 7.3%	21.7B▲ 25.8%	26.76B▲ 23.3%	26.49B▼ 1.0%	25.36B▼ 4.3%	27.43B▲ 8.2%	32.6B▲ 18.8%	33.33B▲ 0%
Gross Margin %	72%	71.25%	65.98%	51.04%	57.69%	57.39%	56.34%	56.79%	67.65%	68.75%
Gross Profit Growth %	3.19%	7.47%	7.31%	25.8%	23.32%	-1.01%	-4.28%	8.18%	18.85%	-
Operating Expenses	9.72B	9.68B	10.81B	17.21B	17.22B	17.22B	16.89B	17.77B	19.91B	20.88B
OpEx % of Revenue	46.78%	42.91%	41.35%	40.47%	37.13%	37.3%	37.52%	36.8%	41.3%	-
Selling, General & Admin	4.75B	4.55B	4.86B	7.65B	7.69B	7.81B	7.68B	7.87B	7.24B	7.28B
SG&A % of Revenue	22.86%	20.17%	18.6%	17.99%	16.57%	16.92%	17.06%	16.28%	15.03%	-
Research & Development	4.97B	5.13B	5.95B	9.56B	9.53B	9.41B	9.21B	9.78B	9.61B	10.03B
R&D % of Revenue	23.92%	22.74%	22.75%	22.48%	20.55%	20.39%	20.46%	20.25%	19.94%	-
Other Operating Expenses	0	0	0	0	0	0	0	127M	3.05B	3M
Operating Income	5.24B▲ 0%	6.39B▲ 22.0%	6.44B▲ 0.7%	4.49B▼ 30.2%	9.54B▲ 112.4%	9.27B▼ 2.8%	8.47B▼ 8.6%	9.66B▲ 14.0%	12.7B▲ 31.5%	12.45B▲ 0%
Operating Margin %	25.22%	28.34%	24.63%	10.56%	20.57%	20.08%	18.82%	20%	26.34%	25.67%
Operating Income Growth %	1.16%	22.05%	0.7%	-30.24%	112.38%	-2.82%	-8.62%	14%	31.46%	-
EBITDA	6.03B	7.03B	8.19B	14.87B	20.23B	19.55B	18.23B	19.26B	16.56B	15.73B
EBITDA Margin %	29.01%	31.16%	31.31%	34.98%	43.6%	42.35%	40.51%	39.87%	34.35%	32.45%
EBITDA Growth %	8.4%	16.64%	16.41%	81.7%	36%	-3.36%	-6.73%	5.63%	-14.03%	-17.22%
D&A (Non-Cash Add-back)	789M	637M	1.75B	10.38B	10.69B	10.28B	9.76B	9.6B	3.86B	3.29B
EBIT	5.33B	6.15B	5.63B	-5.45B	9.43B	8.95B	9.61B	-6.43B	10.68B	10.49B
Net Interest Income	-196M	-183M	-656M	-1.42B	-1.33B	-1.23B	-1.17B	-1.95B	-1.21B	-716M
Interest Income	0	0	0	0	0	0	0	0	300M	300M
Interest Expense	196M	183M	656M	1.42B	1.33B	1.23B	1.17B	1.95B	1.51B	1.02B
Other Income/Expense	-108M	-426M	-1.46B	-11.36B	-1.44B	-1.56B	-32M	-18.04B	-3.37B	-2.85B
Pretax Income	5.13B▲ 0%	5.97B▲ 16.3%	4.97B▼ 16.6%	-6.87B▼ 238.1%	8.1B▲ 217.9%	7.71B▼ 4.8%	8.44B▲ 9.4%	-8.38B▼ 199.3%	9.33B▲ 211.3%	9.6B▲ 0%
Pretax Margin %	24.7%	26.45%	19.03%	-16.16%	17.46%	16.71%	18.75%	-17.35%	19.36%	19.79%
Income Tax	4.16B	1.02B	1.51B	2.12B	1.08B	1.37B	400M	554M	2.27B	2.32B
Effective Tax Rate %	81%	17.11%	30.45%	-30.91%	13.39%	17.74%	4.74%	-6.61%	24.36%	24.22%
Net Income	1.01B▲ 0%	4.92B▲ 388.6%	3.44B▼ 30.1%	-8.99B▼ 361.6%	6.99B▲ 177.8%	6.33B▼ 9.5%	8.03B▲ 26.8%	-8.95B▼ 211.5%	7.05B▲ 178.8%	7.28B▲ 0%
Net Margin %	4.85%	21.81%	13.15%	-21.16%	15.08%	13.71%	17.83%	-18.53%	14.63%	15.01%
Net Income Growth %	-77.41%	388.58%	-30.1%	-361.56%	177.75%	-9.54%	26.84%	-211.5%	178.82%	34.25%
Net Income (Continuing)	975M	4.95B	3.46B	-8.99B	7.01B	6.34B	8.04B	-8.93B	7.06B	7.27B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	106M	96M	100M	60M	60M	57M	55M	53M	33M	34M
EPS (Diluted)	0.61▲ 0%	3.03▲ 396.7%	2.01▼ 33.7%	-3.98▼ 298.0%	3.12▲ 178.4%	2.95▼ 5.4%	3.86▲ 30.8%	-4.41▼ 214.2%	3.45▲ 178.2%	3.56▲ 0%
EPS Growth %	-76.98%	396.72%	-33.66%	-298.01%	178.39%	-5.45%	30.85%	-214.25%	178.23%	33.57%
EPS (Basic)	0.61	3.03	2.02	-3.98	3.15	2.97	3.88	-4.41	3.46	-
Diluted Shares Outstanding	1.65B	1.64B	1.71B	2.26B	2.25B	2.15B	2.08B	2.03B	2.04B	2.04B
Basic Shares Outstanding	1.65B	1.63B	1.71B	2.26B	2.22B	2.13B	2.07B	2.03B	2.04B	2.04B
Dividend Payout Ratio	255.91%	53.11%	77.9%	-	62.85%	73.24%	59.12%	-	71.53%	-

BMY Balance Sheet

Bristol-Myers Squibb Company (BMY) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Total Current Assets	14.85B	17.72B	29.35B	30.19B	33.26B	27.27B	31.77B	29.78B	29.39B	27.21B
Cash & Short-Term Investments	6.81B	8.76B	15.39B	16.45B	17.22B	9.25B	12.28B	10.86B	10.67B	10.49B
Cash Only	5.42B	6.91B	12.35B	14.55B	13.98B	9.12B	11.46B	10.35B	10.21B	9.57B
Short-Term Investments	1.39B	1.85B	3.05B	1.9B	3.24B	130M	816M	513M	464M	912M
Accounts Receivable	6.3B	5.75B	7.68B	10.55B	12.52B	13.94B	15.26B	14.42B	14.53B	9.37B
Days Sales Outstanding	110.68	92.98	107.29	90.6	98.49	110.21	123.79	109	110.01	100.9
Inventory	1.17B	1.2B	4.29B	2.07B	2.1B	2.34B	2.66B	2.56B	2.69B	2.76B
Days Inventory Outstanding	73.15	67.25	176.16	36.36	38.97	43.41	49.45	44.72	62.97	65.89
Other Current Assets	0	899M	1.23B	-685M	1.43B	1.74B	1.56B	1.94B	1.5B	4.6B
Total Non-Current Assets	18.7B	17.27B	100.59B	88.29B	76.05B	69.55B	63.39B	62.82B	60.65B	59.27B
Property, Plant & Equipment	5B	5.03B	6.96B	6.75B	6.97B	7.47B	8.04B	8.36B	9.13B	7.66B
Fixed Asset Turnover	4.15x	4.49x	3.76x	6.30x	6.66x	6.18x	5.60x	5.78x	5.28x	5.92x
Goodwill	6.86B	6.54B	22.49B	20.55B	20.5B	21.15B	21.17B	21.72B	21.75B	21.74B
Intangible Assets	1.21B	1.09B	63.97B	53.45B	42.77B	36.35B	27.48B	23.64B	19.1B	18.24B
Long-Term Investments	2.48B	1.77B	4.17B	4.51B	2.71B	2.19B	2.5B	2.51B	2.51B	7.12B
Other Non-Current Assets	1.53B	2.02B	2.5B	1.88B	1.66B	1.04B	1.43B	2.36B	2.78B	15.83B
Total Assets	33.55B▲ 0%	34.99B▲ 4.3%	129.94B▲ 271.4%	118.48B▼ 8.8%	109.31B▼ 7.7%	96.82B▼ 11.4%	95.16B▼ 1.7%	92.6B▼ 2.7%	90.04B▼ 2.8%	86.48B▲ 0%
Asset Turnover	0.62x	0.64x	0.20x	0.36x	0.42x	0.48x	0.47x	0.52x	0.54x	0.53x
Asset Growth %	-0.46%	4.28%	271.42%	-8.82%	-7.74%	-11.43%	-1.72%	-2.69%	-2.77%	-5.74%
Total Current Liabilities	9.56B	10.65B	18.3B	19.08B	21.87B	21.89B	22.26B	23.77B	23.42B	19.16B
Accounts Payable	2.25B	1.89B	2.44B	2.71B	2.95B	3.04B	3.26B	3.6B	3.58B	4.23B
Days Payables Outstanding	141.03	106.47	100.33	47.57	54.85	56.41	60.54	63	83.69	105.53
Short-Term Debt	987M	1.7B	3.35B	2.34B	4.95B	4.26B	3.12B	2.05B	2.26B	2.31B
Deferred Revenue (Current)	83M	172M	0	0	0	0	0	0	0	0
Other Current Liabilities	909M	5.75B	9.35B	11.65B	11.48B	11.99B	12.79B	14.6B	14.63B	12.62B
Current Ratio	1.55x	1.66x	1.60x	1.58x	1.52x	1.25x	1.43x	1.25x	1.26x	1.26x
Quick Ratio	1.43x	1.55x	1.37x	1.47x	1.43x	1.14x	1.31x	1.15x	1.14x	1.14x
Cash Conversion Cycle	42.8	53.75	183.12	79.4	82.6	97.2	112.7	90.72	89.29	61.26
Total Non-Current Liabilities	12.14B	10.21B	59.94B	61.52B	51.44B	43.81B	43.41B	52.44B	48.12B	47.22B
Long-Term Debt	6.97B	5.65B	43.39B	48.34B	39.6B	35.06B	36.65B	47.6B	42.85B	42.15B
Capital Lease Obligations	0	0	672M	833M	874M	1.26B	1.53B	1.37B	1.83B	5.22B
Deferred Tax Liabilities	0	19M	6.45B	5.41B	4.5B	2.17B	338M	369M	222M	905M
Other Non-Current Liabilities	4.71B	4.07B	9.01B	6.59B	6.13B	5.05B	4.59B	2.87B	3.05B	14.53B
Total Liabilities	21.7B	20.86B	78.25B	80.6B	73.31B	65.7B	65.67B	76.22B	71.53B	66.37B
Total Debt	7.96B	7.35B	47.54B	51.67B	45.6B	40.72B	41.46B	51.2B	47.14B	44.46B
Net Debt	2.54B	438M	35.19B	37.13B	31.62B	31.59B	30B	40.85B	36.93B	34.89B
Debt / Equity	0.67x	0.52x	0.92x	1.36x	1.27x	1.31x	1.41x	3.12x	2.55x	2.55x
Debt / EBITDA	1.32x	1.05x	5.81x	3.47x	2.25x	2.08x	2.27x	2.66x	2.85x	2.83x
Net Debt / EBITDA	0.42x	0.06x	4.30x	2.50x	1.56x	1.62x	1.65x	2.12x	2.23x	2.23x
Interest Coverage	27.18x	33.61x	8.58x	-3.84x	7.07x	7.26x	8.24x	-3.30x	7.08x	10.33x
Total Equity	11.85B▲ 0%	14.13B▲ 19.2%	51.7B▲ 266.0%	37.88B▼ 26.7%	36.01B▼ 5.0%	31.12B▼ 13.6%	29.48B▼ 5.2%	16.39B▼ 44.4%	18.51B▲ 12.9%	20.1B▲ 0%
Equity Growth %	-27.53%	19.25%	265.95%	-26.72%	-4.95%	-13.58%	-5.25%	-44.42%	12.92%	38.74%
Book Value per Share	7.17	8.63	30.20	16.78	16.04	14.50	14.19	8.08	9.07	9.84
Total Shareholders' Equity	11.74B	14.03B	51.6B	37.82B	35.95B	31.06B	29.43B	16.34B	18.47B	20.07B
Common Stock	221M	221M	292M	292M	292M	292M	292M	292M	292M	292M
Retained Earnings	31.16B	34.06B	34.47B	21.28B	23.82B	25.5B	28.77B	14.91B	16.9B	18.29B
Treasury Stock	-19.25B	-19.57B	-25.36B	-26.24B	-31.26B	-38.62B	-43.77B	-43.66B	-43.58B	0
Accumulated OCI	-2.29B	-2.76B	-1.52B	-1.84B	-1.27B	-1.28B	-1.55B	-1.24B	-1.52B	-1.37B
Minority Interest	106M	96M	100M	60M	60M	57M	55M	53M	33M	34M

BMY Cash Flow Statement

Bristol-Myers Squibb Company (BMY) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Cash from Operations	5.28B	7.07B	8.21B	14.05B	16.21B	13.07B	13.86B	15.19B	14.16B	14.16B
Operating CF Margin %	25.39%	31.32%	31.4%	33.05%	34.94%	28.31%	30.8%	31.45%	29.37%	-
Operating CF Growth %	72.5%	33.95%	16.19%	71.16%	15.34%	-19.38%	6.08%	9.6%	-6.81%	-17.75%
Net Income	975M	4.95B	3.46B	-8.99B	7.01B	6.34B	8.04B	-8.93B	7.05B	7.28B
Depreciation & Amortization	789M	637M	1.75B	10.38B	10.69B	10.28B	9.76B	9.6B	4.01B	3.59B
Stock-Based Compensation	199M	221M	441M	779M	583M	457M	518M	507M	553M	555M
Deferred Taxes	453M	45M	-924M	983M	-1.39B	-2.74B	-3.29B	-2.09B	-965M	-1.03B
Other Non-Cash Items	714M	999M	317M	9.92B	578M	955M	744M	15.29B	3.96B	4.5B
Working Capital Changes	2.15B	217M	3.17B	983M	-1.26B	-2.23B	-1.91B	810M	-455M	-1.59B
Change in Receivables	-431M	-429M	752M	-646M	-1.05B	-663M	-995M	264M	-295M	1.38B
Change in Inventory	-29M	-216M	463M	2.67B	13M	-69M	-751M	-486M	-184M	-1M
Change in Payables	320M	-59M	229M	188M	245M	109M	198M	184M	-2M	492M
Cash from Investing	-66M	-2B	-9.91B	-10.86B	-538M	-1.06B	-2.29B	-21.35B	-4.13B	-3.76B
Capital Expenditures	-1.05B	-951M	-836M	-753M	-973M	-1.12B	-1.21B	-1.25B	-1.31B	-1.4B
CapEx % of Revenue	5.08%	4.22%	3.2%	1.77%	2.1%	2.42%	2.69%	2.58%	2.72%	-
Acquisitions	10M	-1.12B	-9.09B	-12.34B	-862M	-2.98B	-260M	-20.72B	-2.87B	-3.9B
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	1.1B
Cash from Financing	-4.08B	-3.54B	7.62B	-1.15B	-16.22B	-16.96B	-9.42B	5.13B	-10.35B	-10.91B
Debt Issued (Net)	991M	-548M	17.65B	3.93B	-6.18B	-5.31B	456M	10.1B	-5.17B	-5.72B
Equity Issued (Net)	-2.47B	-320M	-7.3B	-1.55B	-6.29B	-8B	-5.16B	0	-128M	-134M
Dividends Paid	-2.58B	-2.61B	-2.68B	-4.08B	-4.4B	-4.63B	-4.74B	-4.86B	-5.04B	-5.07B
Share Repurchases	-2.47B	-320M	-7.3B	-1.55B	-6.29B	-8B	-5.16B	0	0	-98M
Other Financing	-22M	-54M	-53M	542M	641M	984M	27M	-106M	0	11M
Net Change in Cash	1.18B▲ 0%	1.49B▲ 25.8%	5.91B▲ 296.6%	2.15B▼ 63.6%	-657M▼ 130.5%	-4.99B▼ 659.7%	2.19B▲ 144.0%	-1.17B▼ 153.4%	-137M▲ 88.3%	-1.29B▲ 0%
Free Cash Flow	4.22B▲ 0%	6.12B▲ 44.9%	7.37B▲ 20.6%	13.3B▲ 80.3%	15.23B▲ 14.5%	11.95B▼ 21.6%	12.65B▲ 5.9%	13.94B▲ 10.2%	12.85B▼ 7.9%	11.91B▲ 0%
FCF Margin %	20.31%	27.1%	28.2%	31.28%	32.84%	25.88%	28.11%	28.87%	26.65%	24.56%
FCF Growth %	128.97%	44.91%	20.59%	80.35%	14.55%	-21.57%	5.88%	10.2%	-7.87%	-9%
FCF per Share	2.55	3.74	4.31	5.89	6.79	5.57	6.09	6.88	6.29	6.29
FCF Conversion (FCF/Net Income)	5.24x	1.44x	2.39x	-1.56x	2.32x	2.07x	1.73x	-1.70x	2.01x	1.64x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

BMY Key Ratios

Bristol-Myers Squibb Company (BMY) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	7.14%	37.88%	10.45%	-20.08%	18.93%	18.85%	26.48%	-39.01%	40.43%	38.96%
Return on Invested Capital (ROIC)	23.67%	33.13%	9.52%	4.16%	10.03%	10.67%	10.4%	12.41%	16.9%	16.9%
Gross Margin	72%	71.25%	65.98%	51.04%	57.69%	57.39%	56.34%	56.79%	67.65%	68.75%
Net Margin	4.85%	21.81%	13.15%	-21.16%	15.08%	13.71%	17.83%	-18.53%	14.63%	15.01%
Debt / Equity	0.67x	0.52x	0.92x	1.36x	1.27x	1.31x	1.41x	3.12x	2.55x	2.55x
Interest Coverage	27.18x	33.61x	8.58x	-3.84x	7.07x	7.26x	8.24x	-3.30x	7.08x	10.33x
FCF Conversion	5.24x	1.44x	2.39x	-1.56x	2.32x	2.07x	1.73x	-1.70x	2.01x	1.64x
Revenue Growth	6.94%	8.59%	15.89%	62.62%	9.1%	-0.49%	-2.5%	7.32%	-0.22%	1.78%

BMY SEC Filings & Documents

Bristol-Myers Squibb Company (BMY) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Apr 30, 2026·SEC

Material company update

Feb 5, 2026·SEC

Material company update

Jan 12, 2026·SEC

10-K Annual Reports

FY 2026

Feb 11, 2026·SEC

FY 2025

Feb 12, 2025·SEC

10-Q Quarterly Reports

FY 2026

Apr 30, 2026·SEC

FY 2025

Oct 30, 2025·SEC

FY 2025

Jul 31, 2025·SEC

BMY Frequently Asked Questions

Bristol-Myers Squibb Company (BMY) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Bristol-Myers Squibb Company (BMY) reported $48.48B in revenue for fiscal year 2025. This represents a 222% increase from $15.06B in 1996.

Bristol-Myers Squibb Company (BMY) saw revenue decline by 0.2% over the past year.

Yes, Bristol-Myers Squibb Company (BMY) is profitable, generating $7.28B in net income for fiscal year 2025 (14.6% net margin).

Dividend & Returns

Yes, Bristol-Myers Squibb Company (BMY) pays a dividend with a yield of 4.34%. This makes it attractive for income-focused investors.

Bristol-Myers Squibb Company (BMY) has a return on equity (ROE) of 40.4%. This is excellent, indicating efficient use of shareholder capital.

Bristol-Myers Squibb Company (BMY) generated $11.91B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More BMY

Bristol-Myers Squibb Company (BMY) financial analysis — history, returns, DCA and operating performance tools

Full BMY Stock Analysis

Analyst verdict, bull/bear case, risk factors and peer comparison

→

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Bristol-Myers Squibb Company(BMY)Earnings, Financials & Key Ratios

BMY Key Insights

✓Strengths

✗Weaknesses

BMY Price & Volume

BMY Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

BMY Recent Earnings

BMY Peer Comparison

Compare BMY vs Peers

vs PFE

vs LLY

Compare Top 5

BMY Income Statement

BMY Balance Sheet

BMY Cash Flow Statement

BMY Key Ratios

BMY SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

BMY Frequently Asked Questions

Explore More BMY

Full BMY Stock Analysis

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation